Medical device manufacturer Prollenium Medical Technologies has announced that its non-animal cross-linked hyaluronic acid dermal filler Revanesse Ultra has been approved by the US Food and Drug Administration (FDA).
According to the company, Revanesse Ultra is now indicated for injection into the mid to deep dermis, for correction of moderate to severe facial wrinkles and folds in adults 22 years of age or more.
Prollenium founder and CEO, Ario Khoshbin, said, "This is definitely one of our proudest moments as an organisation. FDA approval is a culmination of efforts from every single member of our team. As an organisation, we have been working towards this goal from the first day the company opened its doors, and to see it come to fruition is a validation of our vision. The US market and its potential will be an exciting challenge for our team, but one that will have many rewards for our business both in the US and globally."
Prollenium dermal fillers are manufactured in Canada and are distributed in the UK by Boston Medical Group Ltd.